Malignant Pericardial Effusion

García-Riego, Adolfo; Cuiñas, César; Vilanova, Juan José

doi:10.1159/000327865

Cited by 25 publications

(18 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recurrence and survival of patients with malignant pericardial effusion were dependent on the type of primary cancer and the response to chemotherapy. Breast carcinomas were linked to the longest survival and longest interval of latency prior to the onset of the pericardial effusion [48]. …”

Section: Prognosis: Recurrence and Survivalmentioning

confidence: 99%

Malignant Pericardial Effusion

Burazor

Imazio

Markel³

et al. 2013

Cardiology

106

View full text Add to dashboard Cite

Malignant pericardial effusion is a common and serious manifestation in malignancies. The origins of the malignant process include solid tumors or hematological malignancies, while primary neoplasms of the pericardium are less common. In the oncological patient, pericardial effusion may develop by several different mechanisms, namely by direct or metastatic spread of the primary process or as a complication of antineoplastic therapies. In some cases, pericardial effusion may be the first manifestation of the disease, and that is why malignancy must be excluded in every case of an acute pericardial disease with cardiac tamponade at presentation, rapidly increasing pericardial effusion and an incessant or recurrent course. Thus, the definite differentiation of malignant pericardial effusion and rapid diagnosis are of particular therapeutic and prognostic importance. Management of these patients is multidisciplinary and requires team work, but at present there is a need for further research. An individual treatment plan should be established, taking into account cancer stage, the patient's prognosis, local availability and experience. In emergency cases with cardiac tamponade or significant effusion, initial relief can be obtained with pericardiocentesis. Despite the magnitude of this serious problem, little progress has been made in the treatment of pericardial effusion secondary to malignant disease.

show abstract

Section: Prognosis: Recurrence and Survivalmentioning

confidence: 99%

Malignant Pericardial Effusion

Burazor

Imazio

Markel³

et al. 2013

Cardiology

106

View full text Add to dashboard Cite

show abstract

“…The selection of a management plan for these patients depends on the patient's expected survival time and the probability of recurrence. Patients with pericardial effusion with imminent or recurrent tamponade have shown poor survival outcomes (7-9). Therefore, pericardial effusion in cancer patients has been considered a very grave sign.…”

Section: Introductionmentioning

confidence: 99%

Clinical Characteristics of Malignant Pericardial Effusion Associated with Recurrence and Survival

et al. 2010

View full text Add to dashboard Cite

PurposeWe evaluated clinical outcomes after drainage for malignant pericardial effusion with imminent or overt tamponade.Materials and MethodsBetween August 2001 and June 2007, 100 patients underwent pericardiocentesis for malignant pericardial effusion. Adequate follow-up information on the recurrence of pericardial effusion and survival status was available for 98 patients.ResultsRecurrence of effusion occurred in 30 patients (31%), all of whom were diagnosed with adenocarcinoma. Multivariate analysis indicated that adenocarcinoma of the lung (hazard ratio [HR], 6.6; 95% confidence interval [CI], 1.9 to 22.3; p=0.003) and progressive disease despite chemotherapy (HR, 4.3; 95% CI, 1.6 to 12.0; p=0.005) were independent predictors of recurrence. Survival rates three months after pericardiocentesis differed significantly with the type of primary cancer; the rates were 73%, 18%, 90% and 30% in patients with adenocarcinoma of the lung, squamous cell carcinoma of the lung, breast cancer and other cancers, respectively.ConclusionRecurrence and survival of patients with malignant pericardial effusion are dependent on the type of primary cancer and response to chemotherapy. Patients with adenocarcinoma of the lung may be good candidates for surgical drainage to avoid repeated pericardiocentesis, but pericardiocentesis is considered effective as palliative management in patients with other cancers.

show abstract

“…All of these cases demonstrate "more abundant and larger" mesothelial cell clusters that have been described. 4 Other characteristic features of mesothelial cells, such as the scalloped edge of the clusters, dense cytoplasm with peripheral a "halo," and "windows" between cells are present (Fig. 3).…”

Section: Morphologymentioning

confidence: 99%

“…3 Another study collected cases spanning a period of 24 years and identified 375 cases, with 65 cases of malignant pericardial effusion. 4 The sparse literature on the subject can be explained by the relatively rare occurrence of malignant pericardial effusions, and an unwillingness on behalf of clinical teams to perform pericardiocentesis. Unless patients have cardiac tamponade symptoms, there is often a fear of severe complications in obtaining diagnostic material for study.…”

Section: Introductionmentioning

confidence: 99%